These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28651327)

  • 1. Alpha Klotho and Fibroblast Growth Factor-23 Among Alcoholics.
    Quintero-Platt G; González-Reimers E; Rodríguez-Gaspar M; Martín-González C; Pérez-Hernández O; Romero-Acevedo L; Espelosín-Ortega E; Vega-Prieto MJ; Santolaria-Fernández F
    Alcohol Alcohol; 2017 Sep; 52(5):542-549. PubMed ID: 28651327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Klotho and Brain Atrophy in Alcoholism.
    González-Reimers E; Romero-Acevedo L; Espelosín-Ortega E; Martín-González MC; Quintero-Platt G; Abreu-González P; José de-la-Vega-Prieto M; Martínez-Martínez D; Santolaria-Fernández F
    Alcohol Alcohol; 2018 Sep; 53(5):503-510. PubMed ID: 29846497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.
    Silva AP; Mendes F; Carias E; Gonçalves RB; Fragoso A; Dias C; Tavares N; Café HM; Santos N; Rato F; Leão Neves P; Almeida E
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.
    Park MY; Herrmann SM; Saad A; Eirin A; Tang H; Lerman A; Textor SC; Lerman LO
    Clin J Am Soc Nephrol; 2015 Mar; 10(3):443-51. PubMed ID: 25542906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.
    Bergmark BA; Udell JA; Morrow DA; Jarolim P; Kuder JF; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
    Eur J Heart Fail; 2019 Apr; 21(4):462-470. PubMed ID: 30773798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene.
    Han X; Ross J; Kolumam G; Pi M; Sonoda J; King G; Quarles LD
    J Am Soc Nephrol; 2018 Jan; 29(1):69-80. PubMed ID: 28993502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.
    Milovanova LY; Taranova MV; Milovanova SY; Kozlovskaya Lysenko LV; Pasechnik AI; Kozlov VV; Beketov VD; Volkov AV; Ratanov M
    Int Urol Nephrol; 2022 Jul; 54(7):1613-1621. PubMed ID: 34718928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients.
    Fukasawa H; Ishigaki S; Kinoshita-Katahashi N; Niwa H; Yasuda H; Kumagai H; Furuya R
    Nephrology (Carlton); 2014 Dec; 19(12):784-90. PubMed ID: 25185859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor 23 and Klotho as cardiovascular risk factors in heart transplant recipients.
    Przybylowski P; Wasilewski G; Janik L; Kozlowska S; Nowak E; Malyszko J
    Transplant Proc; 2014 Oct; 46(8):2848-51. PubMed ID: 25380933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between plasma fibroblast growth factor-23 and subclinical cardiovascular damages in children with primary hypertension].
    Lin Y; Shi L; Liu YY; Zhang HW; Liu Y; Zhang MM; Huang XL; Hou DQ; Cui XD
    Zhonghua Er Ke Za Zhi; 2019 Jun; 57(6):471-476. PubMed ID: 31216806
    [No Abstract]   [Full Text] [Related]  

  • 13. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice.
    Han X; Cai C; Xiao Z; Quarles LD
    J Mol Cell Cardiol; 2020 Jan; 138():66-74. PubMed ID: 31758962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Potential application of fibroblast growth factor 23-klotho axis in chronic kidney disease].
    Lacroix JS; Urena-Torres P
    Nephrol Ther; 2020 Mar; 16(2):83-92. PubMed ID: 31843356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
    Milovanova LY; Dobrosmyslov IA; Milovanov YS; Taranova MV; Kozlov VV; Milovanova SY; Kozevnikova EI
    Ter Arkh; 2018 Jun; 90(6):48-54. PubMed ID: 30701904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
    Xie J; Yoon J; An SW; Kuro-o M; Huang CL
    J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease.
    Sari F; Inci A; Dolu S; Ellidag HY; Cetinkaya R; Ersoy FF
    J Investig Med; 2017 Feb; 65(2):358-362. PubMed ID: 27733443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
    Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
    Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.